Quarterly ResultMay 7, 2026, 09:22 AM
Iovance Q1 Revenue $71.4M, Net Loss Reduced to $(79.0M)
AI Summary
Iovance Biotherapeutics reported a significant increase in product revenue for Q1 2026, reaching $71.4 million, up from $49.3 million in Q1 2025. The company also substantially reduced its net loss to $(79.0) million, compared to $(116.2) million in the prior year. Iovance continues to commercialize Amtagvi® and Proleukin®, with Amtagvi® approvals in the U.S. and Canada, and plans for further global expansion despite withdrawing initial marketing applications in the EU and UK for resubmission. The company maintains a strong liquidity position with $319.4 million in cash and investments, sufficient to fund operations for at least the next twelve months.
Key Highlights
- Product revenue increased to $71.4 million in Q1 2026 from $49.3 million in Q1 2025.
- Net loss significantly reduced to $(79.0) million in Q1 2026 from $(116.2) million in Q1 2025.
- Net loss per share improved to $(0.19) in Q1 2026 from $(0.36) in Q1 2025.
- Cash, cash equivalents, and restricted cash totaled $202.5 million at March 31, 2026.
- Total current assets grew to $466.5 million at March 31, 2026.
- Net cash used in operating activities decreased to $(72.1) million from $(103.7) million.
- Amtagvi® MAA withdrawn in EU (July 2025) and UK (May 2026) for resubmission.
- Amtagvi® potential approvals pending in Australia (H1 2026) and Switzerland (2027).
Price Impact
More from IOVA